CNSX:PREV

PREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM

Retrieved on: 
Monday, December 4, 2023
Obesity, Research program, FSE, PTPN1, The Company, Research, Diabetes, CSE, Vaccine

PreveCeutical has received direct interest in our diabetes & obesity dual gene therapy program from a world-leading pharmaceutical company established in the diabetes and obesity therapeutic space.

Key Points: 
  • PreveCeutical has received direct interest in our diabetes & obesity dual gene therapy program from a world-leading pharmaceutical company established in the diabetes and obesity therapeutic space.
  • To address the global rise of diabetes and obesity, and in furtherance of PreveCeutical's preventive health care focus, the Research Program builds on years of multi-disciplinary R&D in diabetes and obesity.
  • The rational design of tissue-targeted bioresponsive gene delivery systems (completed) will now be accompanied by gene- and protein-silencing in animal models of obesity and diabetes.
  • PreveCeutical has also approached multiple investment bankers and investors to provide the funding required to complete the preclinical studies.

PreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application

Retrieved on: 
Monday, September 18, 2023
LC-MS/MS, Rat, University, Partnership, CSE, Cerebrospinal fluid, Liquid Tension Experiment 3, The 20/20 Experience – 2 of 2, Serum, Anxiety, Pons, Prefrontal cortex, FSE, Research, Cerebellum, CSF, Experiment, Chronic pain, Pharmacology, Olfactory bulb, Pharmaceutical industry, Medical imaging, Vaccine, Brain, CBD

The company's commitment to advancing medical research is demonstrated through its comprehensive research proposal for a first preclinical study in rats.

Key Points: 
  • The company's commitment to advancing medical research is demonstrated through its comprehensive research proposal for a first preclinical study in rats.
  • The primary objectives of this study include:
    Objective 1: Investigating the potential of sol-gel technology for rapid delivery of CBD to the brain.
  • This includes assessing the amounts achieved, regional distribution, and time course of CBD uptake in the brain (Experiments 1 and 2).
  • Experiment 3: Building upon the outcomes of Experiment 1, the study will assess intranasal CBD doses that yield significant brain exposure in rat models of anxiety and chronic pain.

PreveCeutical Showcases Dynamic Evolution in AI Strategy

Retrieved on: 
Tuesday, September 12, 2023
National Centers for Biomedical Computing, CSE, Natural language, Data management, National Center for Biotechnology Information, API, FSE, Research, OpenAI, Machine learning, Immersion, Hugging Face, Artificial intelligence, AI, Semantic Scholar, AWS, NIH, Information governance, Medical device

VANCOUVER, BC, Sept. 12, 2023 /PRNewswire/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), PreveCeutical Medical Inc. marks today as an important chapter in the journey of PreveCeutical Medical Inc., a pioneering figure in the realm of medical technology.

Key Points: 
  • VANCOUVER, BC, Sept. 12, 2023 /PRNewswire/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), PreveCeutical Medical Inc. marks today as an important chapter in the journey of PreveCeutical Medical Inc., a pioneering figure in the realm of medical technology.
  • The Company unveils a comprehensive narrative around its growing involvement and innovation in the vast domain of Artificial Intelligence (AI).
  • Central to PreveCeutical's AI strategy is its aspiration to harness vast repositories of specialized data, driving the next wave of medical insights and innovations.
  • Stephen Van Deventer, the CEO of PreveCeutical Medical Inc., commented, "Today's AI narrative isn't just an update; it's a testament to our unwavering commitment to driving innovation.

PreveCeutical Engages New to the Street for Production & Broadcasting Services

Retrieved on: 
Thursday, August 31, 2023
Agreement, CSE, Special, FSE, CBS, NBC, Upper Street (group), Suite, Client, Bloomberg, Good, ABC, Fox Business, The Company, News, Television, Mobile phone, Newsmax, USD

VANCOUVER, BC, Aug. 31, 2023 /PRNewswire/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), announces that it has entered into a Service Agreement dated effective September 1, 2023 (the "Agreement") with New to the Street Group LLC ("NTTS"), whereby NTTS will provide production and broadcasting services (the "Services") to the Company involving television, production, media analysis, and procurement.

Key Points: 
  • VANCOUVER, BC, Aug. 31, 2023 /PRNewswire/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), announces that it has entered into a Service Agreement dated effective September 1, 2023 (the "Agreement") with New to the Street Group LLC ("NTTS"), whereby NTTS will provide production and broadcasting services (the "Services") to the Company involving television, production, media analysis, and procurement.
  • NTTS has agreed to accept the following compensation in exchange for performing the Services: The Client agrees to pay New to the Street Group LLC $150,000.00 in total for media production and national TV broadcasting.
  • The remaining balance of $120,000.00 is due on or before March 04, 2024, with all funds being paid in USD.
  • The term of the Agreement shall start September 1, 2023, and shall end February 29, 2024, unless terminated earlier.

PreveCeutical Files Cyclic Peptides And Uses Thereof in the EU and Australia

Retrieved on: 
Monday, July 24, 2023
CSE, FSE, Patent, News, Fine chemical, Cycle

VANCOUVER, BC, July 24, 2023 /PRNewswire/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress Cyclic peptides and uses thereof of its patent families.

Key Points: 
  • VANCOUVER, BC, July 24, 2023 /PRNewswire/ - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress Cyclic peptides and uses thereof of its patent families.
  • PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in Europe and Australia.
  • This is in addition to patent applications having recently been filed in the US and Canada.
  • PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as we continue our clinical process.

PreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development

Retrieved on: 
Tuesday, February 7, 2023
Investigator's brochure, IND, FSE, ICON plc, CSE, Client, ICON, CTA, Biotechnology, Government, Cros, Fine chemical, Pharmaceutical industry

Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 7, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that on February 1, 2023, PreveCeutical has appointed ICON as the clinical research organization (CRO) to complete the following.
  • Construction of a clinical development plan for Phase 1 through pivotal Phase 3 studies.
  • PreveCeutical shall commence the clinical development with ICON in Q1 2023 and work with regulators to seek any potential fast track provisions as we believe that a non-addictive pain analgesic will meet the requirements due to the global abuse of painkillers currently available.
  • PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "Moving forward as PreveCeutical transitions from an R&D company into clinical development, it is our priority to select the best partner for this development.

PreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals

Retrieved on: 
Thursday, January 12, 2023
IND, Schizophrenia, License, Contributor License Agreement, CSE, FSE, South Tyrol Option Agreement, Cannabinoid, NDA, Option, Network affiliate, Licensed production, US, EUR, Pharmaceutical industry

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a License Option Agreement with Endosane Pharmaceuticals GmbH ("Endosane"), a subsidiary of Sanity Group, dated January 10, 2023, pursuant to which Endosane has been granted an option to license the sol-gel technology for the delivery of cannabinoid products on an exclusive basis (the "Option Agreement").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - January 12, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a License Option Agreement with Endosane Pharmaceuticals GmbH ("Endosane"), a subsidiary of Sanity Group, dated January 10, 2023, pursuant to which Endosane has been granted an option to license the sol-gel technology for the delivery of cannabinoid products on an exclusive basis (the "Option Agreement").
  • The purpose of the Option Agreement is for Endosane to evaluate the bioavailability of cannabinoids with the sol-gel technology.
  • Stephen Van Deventer, CEO and Chairman of PreveCeutical, commented, "We are confident that the agreement with Endosane will help facilitate our path to commercialization and revenues.
  • If the option to license the Sol-Gel technology is exercised, in consideration of the rights granted, the License Agreement is expected to contain certain milestones, as listed below, which will require payments to be made by Endosane to PreveCeutical when each milestone is met and approved.